The development of disease-modifying therapies and the identification of novel actionable targets are at the forefront of research in movement disorders. Intending to develop successful therapeutic interventions, research groups around the globe have made great efforts to identify potential new targets. Genetic studies have suggested that lipid and immune abnormalities can be linked to synucleinopathies, providing a new logic for therapeutic interventions that do not focus on protein aggregation but target lipids and inflammation. And since many movement disorders are monogenic or have some well-defined genetic component, they represent strong candidates for antisense oligonucleotide (ASO) therapies.

In this episode, Serge Przedborski, MD, PhD, Columbia University Irving Medical Center, New York, NY; Marina Romero-Ramos, PhD, Aarhus University, Aarhus, Denmark; and Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany, discuss novel findings and topics of interest that may lead to the identification of targets for therapeutic interventions in movement disorders.